HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company constructing doable fresh medicines for sufferers with pediatric cancers, reliable tumors, and a form of cancers, launched this day that it has received a letter from the Nasdaq Itemizing Qualifications workers notifying the Firm that it has regained compliance with Nasdaq’s Itemizing Rule 5550(a)(2) regarding the minimal dispute save requirement for persisted listing on the Nasdaq Capital Market.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company constructing cancer therapies for sufferers looking out fresh remedy alternatives. Salarius’ lead candidate, seclidemstat, is being studied as a doable remedy for pediatric cancers, reliable tumors and a form of cancers with little remedy alternatives. Seclidemstat is at this time in a Part 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Rapidly Music Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Meals and Drug Administration. Salarius can even be constructing seclidemstat for loads of cancers with high unmet clinical want, with a 2nd Part 1/2 clinical explore in evolved reliable tumors, together with prostate, breast, and ovarian cancers. Salarius has received monetary toughen from the Nationwide Pediatric Most cancers Foundation to advance the Ewing sarcoma clinical program and used to be also the recipient of a Product Pattern Award from the Most cancers Prevention and Study Institute of Texas (CPRIT). For extra files, please talk over with salariuspharma.com.
This press open contains “ahead-having a peek statements” within the meaning of the Non-public Securities Litigation Reform Act of 1995. All statements, a form of than statements of historical info, incorporated in this press open are ahead-having a peek statements. These ahead-having a peek statements will more than possible be identified by terms comparable to “live up for,” “doable,” “growth,” “procedure,” “estimate,” “continue,” “will,” “purpose,” “can,” “assume,” “notion,” “enable,” “expect,” “intend,” “purpose,” “provide,” “ready to,” “location,” “venture,” “constructing,” and an identical terms or expressions or the unhealthy thereof. Examples of such statements embrace, however usually are now not little to, statements regarding the following: The situation and anticipated growth and milestones of Salarius’ clinical trials in evolved reliable tumors and Ewing sarcoma; statements associated to Salarius’ constructing cancer therapies for sufferers that want them essentially the most, Salarius’ constructing seclidemstat for loads of cancers with high unmet clinical want; Salarius’ constructing seclidemstat as a doable remedy for pediatric cancers, reliable tumors and a form of cancers with little remedy alternatives. Salarius can even possible now not invent the plans, impress the intentions or meet the expectations or needs disclosed within the ahead-having a peek statements. You mustn’t location undue reliance on these ahead-having a peek statements. These statements are subject to dangers and uncertainties which would possibly per chance also space off valid outcomes and performance to vary materially from those discussed within the ahead-having a peek statements. These dangers and uncertainties embrace, however usually are now not little to, the following: the sufficiency of Salarius’ capital property; the potential of, and desire for, Salarius to pick out additional capital to satisfy Salarius’ enterprise operational wants and to invent its enterprise needs and technique; Salarius’ potential to venture future capital wants and cash utilization and timing and accuracy thereof; the potential of Salarius to get entry to the remaining funding readily available within the market below the CPRIT grant; future clinical trial outcomes and impact of outcomes on Salarius; that the outcomes of analysis and clinical trials usually are now not predictive of future clinical trial outcomes; the sufficiency of Salarius’ intellectual property safety; dangers associated to the drug pattern and the regulatory approval course of; the competitive panorama and a form of industry-associated dangers; market stipulations and regulatory or contractual restrictions which would possibly per chance also impact the potential of Salarius to pick out additional capital; the risk of peculiar prices or a form of uses of Salarius’ cash property; dangers associated to the COVID-19 outbreak; and a form of dangers described in Salarius’ filings with the Securities and Change Price, together with those discussed in Salarius’ quarterly record on Catch 10-Q for the quarter ended September 30, 2020 and in Salarius’ annual record on Catch 10-K for the yr ended December 31, 2019. The ahead-having a peek statements contained in this press open talk finest as of the date of this press open and are in step with administration’s assumptions and estimates as of such date. Salarius disclaims any intent or duty to update these ahead-having a peek statements to reflect occasions or circumstances that exist after the date on which they were made.
Johanna Bennett (Media)